XML 90 R71.htm IDEA: XBRL DOCUMENT v3.22.0.1
Indebtedness - Additional Information (Detail)
12 Months Ended
Dec. 31, 2024
USD ($)
Dec. 20, 2023
USD ($)
Sep. 24, 2020
USD ($)
Dec. 13, 2019
USD ($)
Tranch
Nov. 14, 2017
USD ($)
shares
$ / shares
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Debt Instrument [Line Items]                    
Debt instrument, face amount           $ 1,119,993,000        
Long-term debt           1,096,876,000 $ 992,493,000      
ASU 2020-06 [Member]                    
Debt Instrument [Line Items]                    
Increase in convertible notes           96,800,000        
Decrease in accumulated deficit           (60,200,000)        
Decrease in additional paid-in-capital           (157,000,000.0)        
Convertible Debt, The Term Loan, The Revolver and The Mortgage Loans [Member]                    
Debt Instrument [Line Items]                    
Long-term debt           1,096,900,000        
Interest expense related to debt facilities           63,500,000 59,900,000 $ 30,700,000    
Aggregate long-term debt $ 903,400,000               $ 305,300,000 $ 55,900,000
2024 Convertible Notes [Member]                    
Debt Instrument [Line Items]                    
Debt instrument, face amount         $ 570,000,000.0 $ 569,993,000 $ 569,993,000      
Debt instrument, maturity date         Nov. 15, 2024          
Debt instrument, interest rate per annum         1.50%          
Debt instrument, payment frequency           The 2024 Notes contain customary covenants and events of default, occurrence of which permits the certain holders to accelerate all outstanding obligations, including principal and interest.        
Debt instrument, conversion rate         0.013621          
Debt instrument, conversion price | $ / shares         $ 73.42          
Debt issuance costs         $ 10,600,000          
Effective interest rate percentage             6.90% 6.90%    
Capped calls strike price | $ / shares         73.42          
Capped calls cap price | $ / shares         104.88          
Amount paid for capped calls transactions         $ 50,900,000          
Debt discount           $ 0 $ 98,721,000      
Debt issuance costs           6,320,000 6,510,000      
Aggregate long-term debt           $ 563,673,000 464,762,000      
2024 Convertible Notes [Member] | ASU 2020-06 [Member]                    
Debt Instrument [Line Items]                    
Effective interest rate percentage           1.90%        
Interest expense related to debt facilities           $ 10,700,000 $ 31,400,000 $ 29,900,000    
Increase in convertible notes           96,800,000        
Decrease in accumulated deficit           (60,200,000)        
Decrease in additional paid-in-capital           (157,000,000.0)        
Decrease in interest expense           (22,400,000)        
2024 Convertible Notes [Member] | Common Stock [Member]                    
Debt Instrument [Line Items]                    
Debt instrument, convertible into shares | shares         7,763,552          
Biopharma Credit PLC and Biopharma Credit Investments V (Master) LP [Member] | December 2019 Term Loan [Member]                    
Debt Instrument [Line Items]                    
Debt instrument, maturity date     Dec. 31, 2024 Dec. 20, 2023            
Debt instrument, interest rate per annum               8.50%    
Current borrowing capacity       $ 500,000,000.0            
Number of tranches | Tranch       2            
Biopharma Credit PLC and Biopharma Credit Investments V (Master) LP [Member] | December 2019 Term Loan [Member] | Tranch A [Member]                    
Debt Instrument [Line Items]                    
Current borrowing capacity       $ 250,000,000.0            
Proceeds after debt discount and issuance cost           244,900,000        
Debt discount           9,400,000        
Debt issuance costs           700,000        
Biopharma Credit PLC and Biopharma Credit Investments V (Master) LP [Member] | December 2019 Term Loan [Member] | Tranch A [Member] | Forecast [Member]                    
Debt Instrument [Line Items]                    
Proceeds after debt discount and issuance cost   $ 5,000,000.0                
Biopharma Credit PLC and Biopharma Credit Investments V (Master) LP [Member] | December 2019 Term Loan [Member] | Tranch B [Member]                    
Debt Instrument [Line Items]                    
Current borrowing capacity     $ 300,000,000.0 $ 250,000,000.0            
Proceeds after debt discount and issuance cost           291,100,000        
Debt discount           14,900,000        
Biopharma Credit PLC and Biopharma Credit Investments V (Master) LP [Member] | December 2019 Term Loan [Member] | Tranch B [Member] | Forecast [Member]                    
Debt Instrument [Line Items]                    
Proceeds after debt discount and issuance cost $ 6,000,000.0                  
Biopharma Credit PLC and Biopharma Credit Investments V (Master) LP [Member] | Maximum [Member] | December 2019 Term Loan [Member] | Tranch B [Member]                    
Debt Instrument [Line Items]                    
Debt issuance costs           $ 100,000